We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.72 | 0.81% | 89.57 | 89.55 | 89.56 | 89.65 | 88.78 | 89.06 | 322,328 | 13:16:05 |
From Apr 2022 to Apr 2024
By Cecilia Butini
Sanofi SA said late Tuesday that the U.S. Food and Drug Administration has approved its blockbuster drug Dupixent for use in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
The French pharma company said the approval is directed at those children whose disease isn't adequately controlled with topical prescription therapies, or medicines that are applied directly on the skin.
Sanofi also said that a regulatory filing for this age group is under review by the European Medicines Agency, and that submissions to regulatory authorities in other countries are underway.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
June 08, 2022 01:49 ET (05:49 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
